Physician profile
Sameer Ohri
NPI 1669669339
$3,499.41
in general payments reported to CMS, 2019-2025
31 companies · $1,613 in 2025
The $1,613 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $38.70 · 2021: $199 · 2022: $402 · 2023: $449 · 2024: $518 · 2025: $1,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,847 · Travel and Lodging: $733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,846.69 |
| Travel and Lodging | $733.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $1,086.87 | 2025 | |
| Lilly USA, LLC | $273.40 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $241.80 | 2023-2025 | Freestyle Libre 3 |
| Abbvie INC. | $206.20 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $202.68 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $189.97 | 2019-2022 | |
| Novo Nordisk INC | $182.68 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $158.33 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.05 | 2021-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $120.16 | 2019-2023 | Arexvy |
| Medtronic, INC. | $76.52 | 2023-2024 | Intellis Adaptivestim, Mazor X System |
| Lucid Diagnostics INC. | $72.61 | 2022 | |
| Amgen INC. | $54.52 | 2023 | Repatha, Otezla |
| Smith+Nephew, INC. | $49.72 | 2025 | Stravix, Grafix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.10 | 2021-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $36.89 | 2022 | |
| Novartis Pharmaceuticals Corporation | $34.47 | 2019 | |
| Gilead Sciences, INC. | $32.50 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $28.32 | 2021 | |
| Dexcom, INC. | $28.29 | 2022 | |
| Biogen, INC. | $25.52 | 2025 | Zurzuvae |
| Si-Bone, INC. | $23.18 | 2022 | |
| Edwards Lifesciences Corporation | $23.12 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Sanofi Pasteur INC. | $22.89 | 2023 | |
| Lundbeck LLC | $22.34 | 2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $22.01 | 2023 | Rexulti |
| Ethicon US, LLC | $21.13 | 2022 | |
| Hologic Sales and Service, LLC | $18.73 | 2023 | Thinprep 2000 Processor, Aptima |
| Astellas Pharma US INC | $18.29 | 2019 | |
| Merck Sharp & Dohme LLC | $17.00 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Ohri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.